Boehringer Ingelheim Selects Veeva Development Cloud Worldwide


With Veeva Development Cloud, Boehringer Ingelheim aims to accelerate the development of novel medicines.

Boehringer Ingelheim and Veeva Systems announced Boehringer Ingelheim's selection of Veeva Development Cloud to drive end-to-end processes and information sharing.

As part of Veeva Development Cloud, Boehringer Ingelheim will accelerate clinical development with Vault CDMS, Vault CTMS, Vault eTMF, Vault Study Start-up, and Vault Payments, streamline regulatory activities with Vault Registrations, Vault Submissions, Vault Submissions Publishing, and Vault Submissions Archive, and simplify quality processes with Vault QMS and Vault QualityDocs. The company will also start its journey with the Veeva Digital Trials Platform, using Veeva Site Connect to automate information flow with partner research sites.

The transformation is part of Boehringer Ingelheim’s Medicine Excellence initiative that harnesses technology with the aim to build a ‘One Medicine Platform,’ unifying development processes and data in a centralized platform.

Read more about Boehringer Ingelheim’s selection of Veeva Development Cloud here.

Related Videos
Greg Ball, Founder, ASAP Process Consulting image credit screen shot from video
Janice Chang, CEO, TransCelerate BioPharma @ video screenshot.
Applied Clinical Trials and LabConnect
Cat Hall endpoint Clinical
OM1 Sonja Wustrack
© 2023 MJH Life Sciences

All rights reserved.